Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Rangaswamy Govindarajan to Clinical Trials as Topic

This is a "connection" page, showing publications Rangaswamy Govindarajan has written about Clinical Trials as Topic.

 
Connection Strength
  
 
 
0.429
  
  1. Govindarajan R, Young JW, Harless CL, Hutchins LF. Barriers to clinical trials vary according to the type of trial and the institution. J Clin Oncol. 2007 Apr 20; 25(12):1633-4; author reply 1634.
    View in: PubMed
    Score: 0.241
  2. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006 Oct 01; 24(28):e48.
    View in: PubMed
    Score: 0.058
  3. Khalil O, Govindarajan R, Safar M, Hutchins L, Mehta P. Clinical trial registration and the ICMJE. JAMA. 2005 Jan 12; 293(2):157; author reply 158.
    View in: PubMed
    Score: 0.052
  4. Govindarajan R. Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Williston Park). 2002 Apr; 16(4 Suppl 3):23-6.
    View in: PubMed
    Score: 0.043
  5. Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract. 2019 11; 15(11):e925-e933.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.